Every material Form 8-K Insperity filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Insperity entered into an Eighth Amendment to its credit agreement with Zions Bancorporation (dba Amegy Bank) as administrative agent on December 15, 2025. The amendment increases the revolving credit facility from $650 million to $750 million, lifts the accordion feature from $700 million to $800 million, extends maturity to December 15, 2028, and raises the maximum leverage ratio covenant from 3.00 to 3.75.
Revolving facility increased from $650 million to $750 million
Accordion feature increased from $700 million to $800 million
Facility maturity extended to December 15, 2028
Maximum Leverage Ratio covenant raised from 3.00 to 3.75; EBITDA definition also amended
Insperity reported third-quarter 2025 revenue up 4% to $1.6 billion, but a net loss of $20 million, or $(0.53) per diluted share, compared with net income of $3 million a year earlier, as gross profit fell 15% on higher-than-expected benefits costs. The company also amended its UnitedHealthcare medical coverage arrangement, extending it through 2028 with additional cost savings starting in 2026, and gave its full-year 2025 adjusted EPS guidance of $0.84 to $1.47.
Q3 2025 revenue rose 4% to $1.6 billion; gross profit fell 15% to $195 million
Q3 2025 net loss of $20 million; diluted EPS $(0.53) versus $0.07 in Q3 2024; adjusted EPS $(0.20)
UnitedHealthcare amendment extends the arrangement through 2028 and lets Insperity elect a claim cost limit of $500,000, $750,000, or $1,000,000 per participant per year
Q4 2025 adjusted EPS guidance is $(0.79) to $(0.16); full-year 2025 adjusted EPS guidance is $0.84 to $1.47
Insperity reported second-quarter 2025 revenue up 3% to $1.7 billion, but swung to a net loss of $5 million, or $(0.14) per diluted share, from net income of $18 million a year earlier. The company said higher-than-expected benefits costs drove the decline and lowered its 2025 guidance.
Q2 2025 revenues rose 3% to $1.7 billion; gross profit fell 14% to $223 million.
Q2 2025 adjusted EBITDA was $32 million and adjusted EPS was $0.26, versus $0.86 in Q2 2024.
Updated full-year 2025 guidance: adjusted EPS of $1.81 to $2.51 and adjusted EBITDA of $170 million to $205 million; Q3 2025 adjusted EPS of $0.06 to $0.49.
On July 31, 2025, Insperity also announced an updated HR solutions portfolio, including Insperity HRScale with Workday, which the company said will be available to early adopter customers in 2026.
On June 30, 2025, Insperity's Compensation Committee approved special performance-based equity awards for Chairman and CEO Paul J. Sarvadi and President and COO A. Steve Arizpe, effective July 1, 2025. The awards are tied to the company's stock price and to the planned joint HR solution with Workday, and they vest only after five years of continued service, so they affect shareholders through potential future share issuance tied to the stock price.
Maximum awards are 400,000 performance stock units (PSUs) for Sarvadi and 100,000 for Arizpe.
Full payout requires a 30-day average closing stock price of $225, about 3.6 times the $62.06 grant-date closing price.
Awards are forfeited in full if the stock does not reach the $105 threshold, and vest after five years of continued employment.
The company said the awards aim to retain the executives while the joint solution with Workday launches.
At its 2025 Annual Meeting on May 20, 2025, in Kingwood, Texas, Insperity stockholders approved a First Amendment to the Insperity, Inc. Incentive Plan that adds 620,000 shares available for issuance. The vote also elected four Class III directors, approved an advisory say-on-pay vote, and ratified Ernst & Young LLP as the independent auditor for 2025.
Plan amendment approved with 32,848,275 votes for and 407,914 against, plus 50,281 abstentions and 2,338,231 broker non-votes.
Amendment requires a one-year minimum vesting period for non-employee director awards, with specified exceptions.
Ernst & Young LLP ratified as auditor for the year ending December 31, 2025, with 33,485,884 votes for and 2,141,053 against.
Four Class III directors elected for terms expiring at the 2028 annual meeting: Eli Jones, Randall Mehl, John M. Morphy and Richard G. Rawson.
Insperity reported first-quarter 2025 results and updated its 2025 outlook. Revenues rose 3% to $1.9 billion, but net income fell 35% to $51 million, driven by higher-than-expected healthcare costs. The updated full-year guidance projects adjusted EPS of $2.23 to $3.28, a year-over-year decrease of 8% to 38%, which points to lower earnings for shareholders in 2025.
Q1 2025 net income was $51 million, down 35% from $79 million; diluted EPS was $1.35 versus $2.08 a year earlier.
Revenues rose 3% to $1.9 billion, but gross profit fell 10% to $310 million on higher-than-expected benefits costs.
Full-year 2025 guidance: adjusted EPS of $2.23 to $3.28 and adjusted EBITDA of $190 million to $245 million, both down year over year.
Q2 2025 adjusted EPS guidance is $0.29 to $0.67, a year-over-year decrease of 66% to 22%.
Insperity reported fourth quarter 2024 revenue up 2% to $1.6 billion but a net loss of $9 million, compared with net income of $19 million a year earlier. For full year 2024, revenue rose 1% to $6.6 billion while net income fell 47% to $91 million, and the company gave 2025 guidance of $3.10 to $3.95 in adjusted EPS, which reflects a higher effective income tax rate, and $240 million to $285 million in adjusted EBITDA.
Q4 2024 diluted EPS was $(0.22) versus $0.52 a year earlier; adjusted EPS was $0.05 versus $0.75
Full year 2024 diluted EPS was $2.42 versus $4.47; adjusted EPS was $3.58 versus $5.52
Operating expenses rose 17% in Q4 2024, including about $19 million tied to the Workday strategic partnership
Full year 2025 guidance: adjusted EPS of $3.10 to $3.95 and adjusted EBITDA of $240 million to $285 million
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Insperity filing is on SEC EDGAR ↗. 8-K briefs of other companies →